ANG LI to Risk Assessment
This is a "connection" page, showing publications ANG LI has written about Risk Assessment.
Connection Strength
0.458
-
Thrombosis risk prediction in lymphoma patients: A multi-institutional, retrospective model development and validation study. Am J Hematol. 2024 07; 99(7):1230-1239.
Score: 0.110
-
Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: A systematic review and meta-analysis. J Thromb Haemost. 2019 12; 17(12):2141-2151.
Score: 0.080
-
Derivation and Validation of a Risk Assessment Model for Immunomodulatory Drug-Associated Thrombosis Among Patients With Multiple Myeloma. J Natl Compr Canc Netw. 2019 07 01; 17(7):840-847.
Score: 0.079
-
Utilization patterns and clinical outcomes of rasburicase administration according to tumor risk stratification. J Oncol Pharm Pract. 2020 Apr; 26(3):529-535.
Score: 0.078
-
Development and validation of risk models for hospital-acquired bleeding in medical inpatients: the Medical Inpatients Thrombosis and Hemostasis (MITH) study. J Thromb Haemost. 2026 Feb; 24(2):418-430.
Score: 0.030
-
Factors associated with venous thromboembolism pharmacoprophylaxis initiation in hospitalized medical patients: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024 Dec; 22(12):3521-3531.
Score: 0.028
-
Development and validation of a risk model for hospital-acquired venous thrombosis: the Medical Inpatients Thrombosis and Hemostasis study. J Thromb Haemost. 2024 02; 22(2):503-515.
Score: 0.027
-
External validation of the SAVED score for venous thromboembolism risk stratification in patients with multiple myeloma receiving immunomodulatory drugs. Br J Haematol. 2023 04; 201(2):280-284.
Score: 0.025